4C Capital Announces Its Investment in IGeneX

IGeneX, a leading high complexity, CLIA-certified clinical reference laboratory providing personalized molecular and immunological testing services for Lyme and associated tick-borne diseases to private practice physicians, hospitals, and other clinical reference laboratories worldwide. Based in Palo Alto California, the Company has been committed to providing innovative, state-of-the-art clinical testing for over two decades and places special emphasis on the individual needs of each healthcare provider and each patient. IGeneX provides testing for the entire United States and globally.

Renee McCalla-Watson, Co-Founder and Managing Partner with 4C Capital says, “This is a fantastic opportunity to add even more value to a wonderful company. IGeneX presents a tremendous foundation for organic growth."

Frank Mitchell, Co-Founder and Managing Partner with 4C Capital adds, "4C Capital is excited to support IGeneX, as the company provides specialized services which support physicians’ and practitioners’ delivery of healthcare to their patients. We look forward to working with IGeneX and the management team in support of the continued growth of the business."

In addition to McCalla-Watson and Mitchell, the IGeneX transaction was co-led by 4C Capital Co-Founder and Senior Adviser, Gordon C.C. Liao.

4C Capital is a private investment firm that makes investments in companies for long-term growth. It delivers Capital, Capacity, Competitiveness and Commitment that aligns with management’s vision to drive the next level of enterprise value. 4C leverages its operational expertise, investment sources and network of business opportunity contacts to strengthen and grow the lower middle market companies in which it invests.

Contact:

Renee McCalla-Watson
Phone: 407-900-1663
rwatson@4ccapitalllc.com